Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of Metabolic, Genomic and Proteomic Modifications in Relapsed Glioblastoma. Identification or Prognostic Markers in Patients Undergoing Surgery for Relapsed Glioblastoma.

NCT06430424 is registered in ClinicalTrials.gov with University Hospital, Bordeaux as lead sponsor.

NCT NCT06430424
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06430424 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of Metabolic, Genomic and Proteomic Modifications in Relapsed Glioblastoma. Identification or Prognostic Markers in Patients Undergoing Surgery for Relapsed Glioblastoma.
Lead sponsor
University Hospital, Bordeaux
Phase
Observational
Overall status
Recruiting
Start date
April 5, 2024
Completion date
April 30, 2026
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma idh (isocitrate dehydrogenase) wildtype, relapsed cancer